Health Technology · Biotechnology · NSE: FABTECH · data 2026-10-09
Fabtech Technologies Limited
Health check: Strong (6.6/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹133.22
Market cap
₹620 cr
P/E
11.4
P/B
—
ROE
12.9%
ROCE
9.1%
Debt / equity
0.17
Dividend yield
0.43%
1-year return
-24.4%
52-week high
₹262.8
52-week low
₹131
Operating margin
9.6%
Growth
| Revenue (last 12 months) | ₹418 cr |
| Net profit (last 12 months) | ₹49 cr |
| Sales growth, 3 years (yearly) | 29.2% |
| Profit growth, 3 years (yearly) | 20.8% |
Chart patterns
- Descending triangle — breakdown (key level ₹142.52)
Similar companies
Anthem Biosciences Limited (ANTHEM) · Rubicon Research Limited (RUBICON) · Akums Drugs and Pharmaceuticals Limited (AKUMS) · Fermenta Biotech Ltd (FERMENTA) · Haleos Labs Ltd. (HALEOSLABS)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open FABTECH in NSE Scanner →